Global pharmaceutical company Eli Lilly has entered into a licence and collaboration agreement with Swiss biotechnology company AC Immune.
Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.
Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.
The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.
The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.
German pharmaceutical company Boehringer Ingelheim has signed a research collaboration and licence agreement with French and Canadian biopharmaceutical business Domain Therapeutics.
GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.
AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
Proposed amendments to the EU’s supplementary protection certificate manufacturing waiver risk “further disincentivising investment” in Europe, according to the European Federation of Pharmaceutical Industries and Associations.
The National Health Service England is set to make record-breaking savings after negotiating deals with five manufacturers of low-cost biosimilar versions of the NHS's most expensive drug.